ValuEngine upgraded shares of Heron Therapeutics, Inc. (NASDAQ:HRTX) from a strong sell rating to a sell rating in a research report released on Thursday morning.

Several other equities analysts also recently commented on HRTX. Needham & Company LLC started coverage on Heron Therapeutics in a research report on Monday, February 27th. They issued a buy rating and a $28.00 price objective on the stock. Cantor Fitzgerald set a $30.00 target price on Heron Therapeutics and gave the stock a buy rating in a research report on Sunday, February 26th. Zacks Investment Research upgraded Heron Therapeutics from a strong sell rating to a hold rating in a research report on Tuesday, March 7th. Aegis reiterated a buy rating on shares of Heron Therapeutics in a research report on Tuesday, March 21st. Finally, Jefferies Group LLC reiterated a buy rating and issued a $29.00 target price on shares of Heron Therapeutics in a research report on Monday, April 10th. Two research analysts have rated the stock with a sell rating and ten have given a buy rating to the company. The company has an average rating of Buy and a consensus price target of $34.50.

Heron Therapeutics (HRTX) opened at 13.85 on Thursday. Heron Therapeutics has a 12 month low of $12.21 and a 12 month high of $24.00. The stock’s 50 day moving average price is $14.32 and its 200 day moving average price is $14.12.

Heron Therapeutics (NASDAQ:HRTX) last announced its quarterly earnings data on Wednesday, May 10th. The biotechnology company reported ($1.00) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.94) by $0.06. The firm had revenue of $3.63 million during the quarter, compared to analyst estimates of $1.96 million. Analysts expect that Heron Therapeutics will post ($3.73) EPS for the current year.

WARNING: “Heron Therapeutics, Inc. (HRTX) Upgraded by ValuEngine to “Sell”” was published by Watch List News and is the sole property of of Watch List News. If you are reading this article on another publication, it was stolen and reposted in violation of United States & international copyright laws. The correct version of this article can be viewed at https://www.watchlistnews.com/heron-therapeutics-inc-hrtx-upgraded-by-valuengine-to-sell/1399185.html.

In related news, VP Kimberly Manhard sold 21,542 shares of the business’s stock in a transaction dated Monday, April 24th. The stock was sold at an average price of $15.33, for a total value of $330,238.86. Following the sale, the vice president now directly owns 5,250 shares in the company, valued at $80,482.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 20.31% of the stock is currently owned by insiders.

A number of large investors have recently modified their holdings of HRTX. Rubric Capital Management LP boosted its stake in shares of Heron Therapeutics by 190.9% in the first quarter. Rubric Capital Management LP now owns 1,600,000 shares of the biotechnology company’s stock valued at $24,000,000 after buying an additional 1,050,000 shares during the last quarter. Russell Investments Group Ltd. bought a new stake in shares of Heron Therapeutics during the first quarter valued at $532,000. Mesirow Financial Investment Management Equity Management bought a new stake in shares of Heron Therapeutics during the first quarter valued at $435,000. Nationwide Fund Advisors boosted its stake in shares of Heron Therapeutics by 11.3% in the first quarter. Nationwide Fund Advisors now owns 21,972 shares of the biotechnology company’s stock valued at $330,000 after buying an additional 2,233 shares during the last quarter. Finally, Highbridge Capital Management LLC boosted its stake in shares of Heron Therapeutics by 1.6% in the fourth quarter. Highbridge Capital Management LLC now owns 15,697 shares of the biotechnology company’s stock valued at $206,000 after buying an additional 252 shares during the last quarter.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Heron Therapeutics (NASDAQ:HRTX)

Receive News & Ratings for Heron Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.